Skip to main content
. 2022 Dec 21;8(12):e12518. doi: 10.1016/j.heliyon.2022.e12518

Figure 2.

Figure 2

Antitumor effects of KRpep-2d and oxaliplatin in a CRC PDX model. (A) Growth curves of PDX tumors in each group. No significant difference was observed in tumor volumes between the control and KRpep-2d groups (P > 0.05). Compared to that in the control group, oxaliplatin could significantly inhibit the growth of the xenograft at doses of 5 and 10 mg/kg (P < 0.05). (B) Photo of the PDX tumors harvested from the control, KRpep-2d, and oxaliplatin groups. (C) Tumor weight of all groups. The tumor weights between the control and KRpep-2d groups were not significantly different (P = 0.102). Compared to that in the control group, the tumor weight of the oxaliplatin group at 5 and 10 mg/kg were significantly lower (P = 0.016 and 0.001, respectively). (D) The body weight of mice in each group. The weights of the mice in all groups did not change significantly during the observation period.